This post is 'spot on'. Great analysis. If big pharma thought IPIX had a winner, surely Brilacidin would be long gone from being available, and surely IPIX would have completed a deal adequate to shareholders. Instead, the world waits for 1) Their results 2) perhaps more importantly knowing IPIX's post trial track record: can they do anything of great significance with their post trial results (provided not a failed trial), or will it languish for years and years to come and move on to another new or old asset.